Skip to content
lifestyle.independent.mk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tempest Therapeutics
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 23, 2026
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026
Tempest Therapeutics to Present at H.C. Wainwright Conference
September 8, 2026
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
May 24, 2026
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
May 22, 2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
May 20, 2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 22, 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
April 14, 2026
1
2
Next Page
→